Medicinova INC 8-K filings

MediciNova shareholders elected two directors and ratified auditors, but failed to approve a proposed increase in authorized common stock.

MediciNova, Inc. announced preliminary, unaudited financial results for fiscal year 2025, reporting its first revenue while net losses widened and cash reserves declined.

MediciNova, Inc. has entered into an equity distribution agreement with Lucid Capital Markets, LLC to sell up to $50 million of common stock through an at-the-market offering.

MediciNova, Inc. has entered into a Standby Equity Purchase Agreement with YA II PN, LTD. for up to $30 million in common stock over 36 months, providing flexible capital access.

Medicinova, Inc. announced the results of its 2025 Annual Meeting of Stockholders, confirming the election of a Class III Director, ratification of its independent auditor, and advisory approval of executive compensation and a three-year frequency for future say-on-pay votes.

MediciNova updates its investor presentation, showcasing progress in clinical trials for MN-166 and MN-001 and other partnered programs.

MediciNova's 2024 annual meeting saw the election of two Class II directors and the ratification of BDO USA, P.C. as the company's independent auditor.

MediciNova's Vice President, Geoffrey OBrien, has announced his retirement from full-time employment, effective April 2, 2024, and will transition to a consulting role with the company.